Business
Shenguan : Announces 2024 Annual Results
Shenguan : Announces 2024 Annual
About this update from Shenguan Holdings (group) Limited
[{"type":"text","content":"\n \n Immediate Release\n \n \n 24 March 2025\n \n SHENGUAN HOLDINGS (GROUP) LIMITED\n \n \n 神冠控股（集團）有限公司\n \n \n （於開曼群島註冊成立的有限公司）\n \n \n （股份代號：00829）\n \n \n Shenguan Holdings Announces 2024 Annual Results\n \n \n Maintaining Market Leadership with Significant Achievements in Diversified Business Expansion\n \n \n (24 March 2025 - Hong Kong) Shenguan Holdings (Group) Limited (\"Shenguan Holdings\" or the \"Company\", Stock Code: 00829.HK) is pleased to announce the consolidated annual results of the Company and its subsidiaries (collectively referred to as the \"Group\") for the year ended 31 December 2024 (the \"Year\").\n \n \n In 2024, the Group accelerated the development of the grand health industry under the \"Three Developments and One Core\" strategy, the Group has successfully launched six series of new products of collagen sausage casings, to further consolidate its leading position in the collagen sausage casings market. At the same time, the Group intensifies its expansion in three major industries, namely collagen food products, collagen skincare products and collagen medical biomaterials. During the year, the Group recorded revenue of approximately RMB1,016.8 million. In the Prior Year, there was an after-tax gain of approximately RMB29.8 million in respect of other gains on the assignment of marketing authorisations for pharmaceutical products while there was no similar gain in the Year and a decrease in revenue of approximately 8.4%, the profit attributable to owners of the parent decreased by only approximately 14.7% to approximately RMB26.7 million for the Year from approximately RMB31.2 million for the Prior Year as a result of the improvement in the gross profit margin, favourable sales of medical collagen raw materials and stringent control of operating expenses in the Year. However, if the above other gains on the assignment of marketing authorisations for pharmaceutical products were excluded, the profit attributable to owners of the parent for the Prior Year would be approximately RMB1.4 million, which in fact represented a significant increase for the Year.\n \n \n Collagen Sausage Casings: New Product Series Garner Unanimous Customer Praise and Standardised Management Continuously Improved\n \n \n During the Year, the Group successfully developed and launched six new products of the collagen sausage c...